close
References
  1. Bose G, Freedman MS. Precision medicine in the multiple sclerosis clinic: selecting the right patient for the right treatment. Mult Scler. 2020;26(5):540-547.
  2. Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA. 2019;321(2):175-187.
  3. Burton JM, O’Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev. 2012;12:CD006921.
  4. Comi G, Radaelli M, Sørensen PS. Evolving concepts in the treatment of relapsing multiple sclerosis Lancet. 2017;389(10076):1347-1356.
  5. De Stefano N, Stromillo ML, Giorgio A, et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87(1):93-99.
  6. D’hooghe MB, Nagels G, Bissay V, Keyseret JD. Modifiable factors influencing relapses and disability in multiple sclerosis. Mult Scler. 2010;16(7):773-785.
  7. Di Pauli F, Reindl M, Ehling R, et al. Smoking is a risk factor for early conversion to clinically definite multiple sclerosis. Mult Scler. 2008;14(8):1026-1030.
  8. Fox RJ, Rae-Grant AD, Bethoux F. Multiple Sclerosis and Related Disorders. 2nd ed. Demos Medical; 2018.
  9. Fox RJ, Cohen A. Multiple sclerosis: the importance of early recognition and treatment. Cleve Clin J Med. 2001;68(2):157-171.
  10. Galati A, Kaisey M. Multiple sclerosis misdiagnosis. Prac Neurol. 2019;18(2):39-42.
  11. Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016;9 Suppl:S5-S48.
  12. Hansen MR, Okuda DT. Multiple sclerosis in the contemporary age: understanding the millennial patient with multiple sclerosis to create next-generation care. Neurol Clin. 2018;36(1):219-230.
  13. Heine M, Verschuren O, Hoogervorst EJ, et al; TREFAMS-ACE study group. Does aerobic training alleviate fatigue and improve societal participation in patients with multiple sclerosis? A randomized controlled trial. Mult Scler. 2017;23(11):1517-1526.
  14. Kappus N, Weinstock-Guttman B, Hagemeier J, et al. Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87(2):181-187.
  15. Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. MSJ. 2017;23(9):1233-1240.
  16. Krieger SC, Cook K, De Nino S, Fletcher M. The topographical model of multiple sclerosis: a dynamic visualization of disease course. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e279.
  17. Latimer-Cheung AE, Martin Ginis KA, Hicks AL, et al. Development of evidence-informed physical activity guidelines for adults with multiple sclerosis. Arch Phys Med Rehabil. 2013;94(9):1829-1836.
  18. Le Page E, Veillard D, Laplaud DA, et al; COPOUSEP investigators, West Network for Excellence in Neuroscience. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet. 2015;386(9997):974-981. 
  19. Liu S, Liu X, Chen S, Xiao Y, Zhuang W. Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: a meta-analysis of randomized controlled trials. PLoS One. 2017;12(11):e0188644.
  20. Mamilly A, Aslan A, Adeeb N, Asfari AA, Cuellar H. Tumefactive multiple sclerosis of the cervical spinal cord: a rare case report. Cureus. 2020;12(1):e6754.
  21. MS International Federation. Statistics. www.atlasofms.org/map/united-states-of-america/epidemiology/number-of-people-with-ms. Accessed December 20, 2020.
  22. Multiple Sclerosis Trust. Lumbar puncture. https://mstrust.org.uk/a-z/lumbar-puncture. Accessed December 20, 2020.
  23. National Multiple Sclerosis Society. How many people live with MS? www.nationalmssociety.org/What-is-MS/How-Many-People. Accessed December 20, 2020.
  24. National Multiple Sclerosis Society. Vitamin D. www.nationalmssociety.org/Research/Research-News-Progress/Vitamin-D. Accessed December 20, 2020.
  25. Nelson F, Poonawalla AH, Hou P, Huang F, Wolinsky JS, Narayana PA. Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. AJNR Am J Neuroradiol. 2007;28(9):1645-1649.
  26. Ozcan ME, Ince B, Bingöl A, et al. Association between smoking and cognitive impairment in multiple sclerosis. Neuropsychiatr Dis Treat. 2014;10:1715-1719.
  27. Pittas F, Ponsonby AL, van der Mei IAF, et al. Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J Neurol. 2009;256(4):577-585.
  28. Prakash RS, Snook EM, Motl RW, Kramer AF. Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis. Brain Res. 2010;1341:41-51.
  29. Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72(2):152-158.
  30. Signori A, Schiavetti I, Gallo F, Sormani MP. Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials. Eur J Neurol. 2015;22(6):960-966.
  31. Tettey P, Simpson S Jr., Taylor BV, van der Mei IAF. Vascular comorbidities in the onset and progression of multiple sclerosis. J Neurol Sciences. 2014;347(1-2):23-33.
  32. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173.
  33. Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis - success from bench to bedside. Nat Rev Neurol. 2019;15(1):53-58.
  34. Wallin MT, Culpepper WJ, Campbell JD, et al; US Multiple Sclerosis Prevalence Workgroup. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029-e1040.
  35. Wattjes MP, Steenwijk MD, Stangel M. MRI in the diagnosis and monitoring of multiple sclerosis: an update. Clin Neuroradiol. 2015;25 Suppl 2:157-165.
  36. Wattjes MP, Lutterbey G, Gieseke J, et al. Double inversion recovery brain imaging at 3T: diagnostic value in the detection of multiple sclerosis lesions. AJNR Am J Neuroradiol. 2007;28(1):54-59.